Contact
searchSearch
HMP Global
Login
Test Your Knowledge

Quiz: Does Targeting CD30 Lead to Improved Outcomes in PTCL?

11/12/2021

Recent News

News
Darolutamide Plus ADT and Radiotherapy Significantly Improves Metastasis-Free Survival in High-Risk Prostate Cancer
10/24/2026
Stephanie Holland
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP trial demonstrated that adding darolutamide to androgen deprivation therapy and radiotherapy significantly improved metastasis-free survival in patients with very high-risk localized or biochemically...
Results from the DASL-HiCaP...
10/24/2026
Oncology
News
Tarlatamab Plus Durvalumab Significantly Improves Overall Survival in Patients With Extensive-Stage Small Cell Lung Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3 DeLLphi-305 trial demonstrated that tarlatamab plus durvalumab significantly improved overall survival, progression-free survival, and objective response compared with durvalumab alone as first-line maintenance...
Results from the phase 3...
10/24/2026
Oncology
News
VOLGA Trial Demonstrates Significant Survival Benefit With Durvalumab Plus Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
10/24/2026
Stephanie Holland
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA trial demonstrated that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival in cisplatin-ineligible or cisplatin-refusing patients with...
Results from the phase 3 VOLGA...
10/24/2026
Oncology
News
Intismeran Plus Pembrolizumab Significantly Improves Recurrence-Free Survival in Resected High-Risk Melanoma
10/24/2026
Stephanie Holland
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3 INTerpath-001 trial demonstrated that intismeran plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with resected high-risk...
Results from the phase 3...
10/24/2026
Oncology
FDA Approval
FDA Grants Full Approval to Pembrolizumab for Patients With Tumor Mutational Burden-High Solid Tumors
10/23/2026
Emily Estrada
Based on results from the KEYNOTE-158 trial, the FDA converted pembrolizumab’s accelerated approval to traditional approval for adult and pediatric patients with previously treated unresectable or metastatic tumor mutational burden-high...
Based on results from the KEYNOTE-158 trial, the FDA converted pembrolizumab’s accelerated approval to traditional approval for adult and pediatric patients with previously treated unresectable or metastatic tumor mutational burden-high...
Based on results from the...
10/23/2026
Oncology
FDA Approval
FDA Approves Dostarlimab for Patients With MSI-H/dMMR Locally Advanced Rectal Cancer
10/19/2026
Emily Estrada
The FDA granted accelerated approval to dostarlimab for patients with stage II/III MSI-H/dMMR locally advanced rectal cancer, establishing an immunotherapy-based treatment option supported by sustained clinical complete responses and the...
The FDA granted accelerated approval to dostarlimab for patients with stage II/III MSI-H/dMMR locally advanced rectal cancer, establishing an immunotherapy-based treatment option supported by sustained clinical complete responses and the...
The FDA granted accelerated...
10/19/2026
Oncology
FDA Approval
FDA Expands Nogapendekin Alfa Inbakicept Plus Bacillus Calmette-Guérin Approval to Include High-Grade Papillary-Only Bladder Cancer
10/14/2026
Emily Estrada
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication...
10/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
News
Iberdomide Plus Daratumumab and Dexamethasone Significantly Improves PFS in Relapsed or Refractory Multiple Myeloma
10/08/2026
Stephanie Holland
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3...
10/08/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use